{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=73",
    "query": {
      "intervention": "Placebo Comparator A",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 27155,
    "total_pages": 2716,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T16:47:58.716Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00617032",
      "title": "Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tgAAC94 gene therapy vector",
          "type": "GENETIC"
        },
        {
          "name": "tgAAC94 placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Targeted Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2004-02",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2008-02-15",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617032"
    },
    {
      "nct_id": "NCT06097663",
      "title": "A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Heart Disease",
        "Clonal Hematopoiesis of Indeterminate Potential (CHIP)"
      ],
      "interventions": [
        {
          "name": "MAS825",
          "type": "DRUG"
        },
        {
          "name": "MAS825 Placebo",
          "type": "DRUG"
        },
        {
          "name": "DFV890",
          "type": "DRUG"
        },
        {
          "name": "DFV890 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2024-02-15",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Nashville, Tennessee",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097663"
    },
    {
      "nct_id": "NCT05058287",
      "title": "Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use",
        "Lumbar Spinal Stenosis",
        "Pain, Postoperative",
        "Pain, Back"
      ],
      "interventions": [
        {
          "name": "Depo-Medrol 40Mg/Ml Suspension for Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-11-05",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05058287"
    },
    {
      "nct_id": "NCT05669014",
      "title": "A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Inflammatory Myositis"
      ],
      "interventions": [
        {
          "name": "Daxdilimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-12-04",
      "completion_date": "2025-07-02",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05669014"
    },
    {
      "nct_id": "NCT06816433",
      "title": "Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Intervention D SLS-002",
          "type": "DRUG"
        },
        {
          "name": "Intervention D Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Coalition for Adaptive Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 200,
      "start_date": "2028-05",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 9,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Tripler AMC",
          "state": "Hawaii"
        },
        {
          "city": "Fort Thomas",
          "state": "Kentucky"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06816433"
    },
    {
      "nct_id": "NCT05093933",
      "title": "A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Vericiguat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6106,
      "start_date": "2021-11-02",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 84,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 74 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05093933"
    },
    {
      "nct_id": "NCT01496352",
      "title": "DFA-02 in Patients Undergoing Colorectal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "DFA-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited, India",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-02",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-01",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 5,
      "location_summary": "Florence, Alabama • Tampa, Florida • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496352"
    },
    {
      "nct_id": "NCT01050647",
      "title": "Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pregnancy Complications"
      ],
      "interventions": [
        {
          "name": "17-Hydroxyprogesterone Caproate",
          "type": "DRUG"
        },
        {
          "name": "Caster Oil injections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 21,
      "start_date": "2010-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 2,
      "location_summary": "San Jose, California • Stanford, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050647"
    },
    {
      "nct_id": "NCT03388138",
      "title": "Clinical Evaluation of Etafilcon A With Ketotifen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Visual Acuity"
      ],
      "interventions": [
        {
          "name": "etafilcon A with ketotifen",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "1-Day ACUVUE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DEVICE"
      ],
      "sponsor": "Johnson & Johnson Vision Care, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 143,
      "start_date": "2017-12-06",
      "completion_date": "2018-02-09",
      "has_results": true,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Maitland, Florida • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Pittsburg",
          "state": "Kansas"
        },
        {
          "city": "Vestal",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388138"
    },
    {
      "nct_id": "NCT06717438",
      "title": "Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Jordan's Syndrome",
        "PPP2R5D Neurodevelopmental Disorder"
      ],
      "interventions": [
        {
          "name": "BPN14770",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "9 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-05-13",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-11-22T16:47:58.716Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06717438"
    }
  ]
}